Abstract
Development of technology for production, purification and stabilisation of subtypes of recombinant chimeric multiepitopic antigens OspC, OspA, DbpA derived from Borelia burgdorferi. Synthesis of glycolipid antigen (acylated cholesteryl-galactoside). Construction of experimental vaccine and evaluation of efficacy and safety of various adjuvans (liposomes, oil adjuvans, alum, synthetic immunomodulators). Selection of candidate vaccines according to stability, safety efficacy and economic criteria. Preparation of operation procedures for preparation and characterisation of candidate vaccines with recombinant antigens and testing their efficacy, safety and protectivity on in vivo models (mouse, rabbit, dog)